Understanding how platelet strength relates to bleeding risk in immune thrombocytopenia
Leveraging platelet contraction cytometry for immune thrombocytopenia
This study is looking at how strong individual platelets are in people with immune thrombocytopenic purpura (ITP) to see if that can help doctors figure out who might be at a higher risk for bleeding and need treatment, so they can avoid giving unnecessary treatment to those who are less at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11042700 on NIH RePORTER |
What this research studies
This research investigates the relationship between the contractile force of individual platelets and the risk of bleeding in patients with immune thrombocytopenic purpura (ITP). By utilizing a high-throughput platelet contraction cytometer, the study aims to measure the strength of platelets in both children and adults diagnosed with ITP. The goal is to identify a potential biomarker that could help clinicians determine which patients are at higher risk for bleeding and may require treatment, thereby avoiding unnecessary side effects for those at lower risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and adults diagnosed with immune thrombocytopenic purpura (ITP).
Not a fit: Patients with other bleeding disorders or those without a diagnosis of immune thrombocytopenic purpura may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved risk assessment and treatment strategies for patients with immune thrombocytopenia, ultimately reducing the incidence of serious bleeding events.
How similar studies have performed: While the approach of using platelet contractile force as a biomarker is novel, preliminary results suggest a strong correlation with bleeding risk, indicating potential for success.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Myers, David Richard — Emory University
- Study coordinator: Myers, David Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.